Psychedelics for Serious Illness: An update on the state of science for psychedelics, and what all clinicians should know as they enter this uncharted territory.

An update on the state of science for psychedelics, and what all clinicians should know as they enter this uncharted territory.
Articles about psychedelic treatments for persistent depression, PTSD, and substance use disorder seem to be everywhere. Rarely a week goes by without a newly published study appearing in a peer-reviewed medical journal, usually followed by reports of the study in prominent news outlets.

Anyone born after 1970 may find themselves wondering, “What’s going on?” Until recently, psychedelics seemed to be artifacts of a bygone era of anti-war protests, hippies, Hair, and classic vinyl.

Here’s what you need to know.

1. These drugs have a long history.

Psychedelics actually have a long history. Archaeological evidence shows that early humans ingested specific plants and mushrooms, which produce chemicals with psychedelic properties. For millennia, indigenous people in Asia, Central and South America have used experiences induced by psychedelics as central components of sacred ceremonies. Western medicine’s examination of these drugs dates to the synthesis of LSD (lysergic acid diethylamide) in 1938 by Albert Hoffman, a Swiss chemist working for the Sandoz pharmaceutical company. Hofmann had been researching vasoactive compounds and initially set aside LSD. In 1943 he inadvertently absorbed some of the chemical transcutaneously and had the first LSD-induced psychedelic experience.

Recognizing its intense psychic properties, Sandoz offered LSD to psychiatrists who were interested in exploring its therapeutic potential. From 1950 through early 1970s, licensed physicians could administer or prescribe LSD to patients. Research flourished in the form of bench science, case studies and small, non-randomized trials. Before falling victim to the excesses and cultural-political tensions of the era, more than 1,000 articles about psychedelics were published in the medical literature. Then the Nixon administration reclassified psychedelics as Schedule I drugs, signifying high potential for abuse and no legitimate use. Research ceased.

But seeds had been planted in the minds of a handful of clinicians and investigators. Early in the present century the FDA granted permission to researchers at UCLA, NYU, and Johns Hopkins universities to conduct small, well-designed trials of psilocybin-assisted therapy. Consistent with previous findings, a large majority of patients with cancer and concomitant depression or anxiety demonstrated substantial improvements on standard scales. Notably, these benefits were often sustained through months of follow up. Publication of these studies ushered in the current renaissance of psychedelic-assisted therapies.

Read Full Article

Latest Blog Posts

The Healing Power of Ketamine: A Conversation with Dr. Sunil Aggarwal

The Healing Power of Ketamine: A Conversation with Dr. Sunil Aggarwal

In the world of modern medicine, few voices resonate as profoundly as Dr. Sunil Aggarwal. As a palliative care physician and ketamine expert, Dr. Aggarwal has been at the forefront of groundbreaking therapies that challenge traditional approaches to healing. His recent conversation with Marc Marcel on the Marc Marcel Podcast offers a rare glimpse into the science, soul, and stigma surrounding psychedelic medicine. Key Topics Covered in the Episode: Psychedelic Healing: How ketamine and other psychedelic therapies are transforming the way we approach mental health and trauma recovery. End-of-Life Care: The role of ketamine in providing comfort and relief for ...

Read More
Psychedelic Renaissance in Washington: A New Era for Mental Health and Wellness

Psychedelic Renaissance in Washington: A New Era for Mental Health and Wellness

Washington state is on the cusp of a significant transformation in mental health and wellness, driven by a growing movement to decriminalize and medically integrate psychedelic substances like psilocybin. While efforts to fully legalize psychedelic mushrooms statewide have faced hurdles, the dedicated work of medical professionals, activists, and researchers is paving the way for a more progressive approach to mental health care. Leading the Way: AIMS Institute and Dr. Sunil Aggarwal At the forefront of this movement is Dr. Sunil Aggarwal, a renowned palliative care physician and co-director of the Advanced Integrative Medical Science (AIMS) Institute in Seattle. Dr. Aggarwal ...

Read More
Envisioning Drug Peace in the Entheogenic Reformation:

Envisioning Drug Peace in the Entheogenic Reformation:

Incorporating the Spiritual Geography of Psychoactives in Post-Prohibition Public Health  Greetings, I am Sunil Aggarwal, a doctor and medical geographer and a member of the Sacred Garden Community. I hail from Oklahoma, a child of Indian Immigrants, and I live today in Seattle, which rests on the unceded territory of the co-Salish Duwamish People, and I am so honored to join you here in Portland, a city which rests on the traditional village sites of the Multnomah, Wasco, Cowlitz, Kathlamet, Clackamas, Bands of Chinook, Tualatin, Kalapuya, Molalla, and many others who made their homes along the Columbia River. The title ...

Read More
Call Us Text Us
Skip to content